153 related articles for article (PubMed ID: 31842117)
1. Chemotherapy in Esthesioneuroblastoma/Olfactory Neuroblastoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) 1973-2015 Database.
Cranmer LD; Chau B; Rockhill JK; Ferreira M; Liao JJ
Am J Clin Oncol; 2020 Mar; 43(3):203-209. PubMed ID: 31842117
[TBL] [Abstract][Full Text] [Related]
2. Is sex an independent prognostic factor in esthesioneuroblastoma?
Stokes WA; Camilon PR; Banglawala SM; Nguyen SA; Harvey R; Vandergrift WA; Schlosser RJ
Am J Rhinol Allergy; 2015; 29(5):369-72. PubMed ID: 26358349
[TBL] [Abstract][Full Text] [Related]
3. Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?
Eich HT; Müller RP; Micke O; Kocher M; Berthold F; Hero B
Strahlenther Onkol; 2005 Jun; 181(6):378-84. PubMed ID: 15925980
[TBL] [Abstract][Full Text] [Related]
4. Esthesioneuroblastoma: A Patterns-of-Care and Outcomes Analysis of the National Cancer Database.
Orton A; Boothe D; Evans D; Lloyd S; Monroe MM; Jensen R; Shrieve DC; Hitchcock YJ
Neurosurgery; 2018 Nov; 83(5):940-947. PubMed ID: 29481629
[TBL] [Abstract][Full Text] [Related]
5. Absence of Survival Improvement for Patients with Esthesioneuroblastoma Over the Past 2 Decades: A Population-Based Study.
Vuong HG; Nguyen DD; El-Rassi E; Ngo TNM; Dunn IF
World Neurosurg; 2022 Jan; 157():e245-e253. PubMed ID: 34628034
[TBL] [Abstract][Full Text] [Related]
6. Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma.
Miller KC; Marinelli JP; Van Gompel JJ; Link MJ; Janus JR; Foote RL; Price KA; Garcia J; Rivera M; Chintakuntlawar AV
Head Neck; 2019 May; 41(5):1335-1341. PubMed ID: 30536472
[TBL] [Abstract][Full Text] [Related]
7. Patient, disease, and treatment factors associated with overall survival in esthesioneuroblastoma.
Carey RM; Godovchik J; Workman AD; Kuan EC; Parasher AK; Chen J; Palmer JN; Adappa ND; Newman JG; Brant JA
Int Forum Allergy Rhinol; 2017 Dec; 7(12):1186-1194. PubMed ID: 29045018
[TBL] [Abstract][Full Text] [Related]
8. Geographic and Socioeconomic Factors on Survival in Esthesioneuroblastoma.
Mikhael ST; Tadrosse AF; Tadrosse MF; Yassa A; Mikhael MT; Barinsky GL; Grube JG; Fang CH; Eloy JA
Laryngoscope; 2021 Jul; 131(7):E2162-E2168. PubMed ID: 33347619
[TBL] [Abstract][Full Text] [Related]
9. Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma.
Eich HT; Hero B; Staar S; Micke O; Seegenschmiedt H; Mattke A; Berthold F; Müller RP
Strahlenther Onkol; 2003 Apr; 179(4):233-40. PubMed ID: 12707712
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic endonasal resection of esthesioneuroblastoma: A single center experience of 24 patients.
Feng L; Fang J; Zhang L; Li H; Zhou B; Chen X; Li Y; Han D
Clin Neurol Neurosurg; 2015 Nov; 138():94-8. PubMed ID: 26310690
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and overall survival in pediatric versus adult esthesioneuroblastoma: A population-based study.
Berger MH; Lehrich BM; Yasaka TM; Fong BM; Hsu FPK; Kuan EC
Int J Pediatr Otorhinolaryngol; 2021 May; 144():110696. PubMed ID: 33812144
[TBL] [Abstract][Full Text] [Related]
12. Survival impact of postoperative radiotherapy in patients with olfactory neuroblastoma: 513 cases from the SEER database.
Duo GS; Feng JL; Zhang ZY; Wang LJ
Cancer Radiother; 2022 Sep; 26(5):663-669. PubMed ID: 35249817
[TBL] [Abstract][Full Text] [Related]
13. Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine.
Arshi A; Sharim J; Park DY; Park HY; Yazdanshenas H; Bernthal NM; Shamie AN
Spine J; 2017 May; 17(5):645-655. PubMed ID: 27856382
[TBL] [Abstract][Full Text] [Related]
14. The role of chemotherapy in the management of olfactory neuroblastoma: A 40-year surveillance, epidemiology, and end results registry study.
Brisson RJ; Quinn TJ; Deraniyagala RL
Health Sci Rep; 2021 Jun; 4(2):e257. PubMed ID: 33969231
[TBL] [Abstract][Full Text] [Related]
15. Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients.
Xiong L; Zeng XL; Guo CK; Liu AW; Huang L
BMC Cancer; 2017 Apr; 17(1):254. PubMed ID: 28399835
[TBL] [Abstract][Full Text] [Related]
16. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.
Jethanamest D; Morris LG; Sikora AG; Kutler DI
Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):276-80. PubMed ID: 17372086
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and Prognosis of Primary Head and Neck Angiosarcomas: A Surveillance, Epidemiology, and End Results Program (SEER) Analysis of 1250 Cases.
Lee KC; Chuang SK; Philipone EM; Peters SM
Head Neck Pathol; 2019 Sep; 13(3):378-385. PubMed ID: 30357539
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors and outcome of esthesioneuroblastoma].
Zhao LJ; Gao L; Xu GZ; Li SY; Xiao GL
Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):561-4. PubMed ID: 16438858
[TBL] [Abstract][Full Text] [Related]
19. Impact of esthesioneuroblastoma treatment delays on overall patient survival.
Tsutsumi K; Ahmed KH; Goshtasbi K; Torabi SJ; Mohyeldin A; Hsu FPK; Kuan EC
Laryngoscope; 2023 Apr; 133(4):764-772. PubMed ID: 35460271
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
McElroy EA; Buckner JC; Lewis JE
Neurosurgery; 1998 May; 42(5):1023-7; discussion 1027-8. PubMed ID: 9588546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
